Webform

ZERO Summit 2022 banner

Biomarkers and Personalized Medicine

Graphic from Biomarkers and Personalized Medicine presentation

Dr. Daniel Spratt discusses the latest developments in biomarkers. Early detection of prostate cancer is largely carried out using assessment of prostate-specific antigen (PSA) level; yet it cannot reliably discriminate between benign pathologies and clinically significant forms of prostate cancer. To overcome the current limitations of PSA, new urinary and serum biomarkers have been developed in recent years.

This session was part of our VIRTUAL ZERO Prostate Cancer Summit, which took place from March 4 to 8, 2022.

Watch

Contributor

A young male doctor with brown wavy hair wearing his white coat standing in a library
Daniel Spratt, MD, Chair Department of Radiation Oncology

Dr. Daniel Spratt is the Chairman and Professor of Radiation Oncology at University Hospitals (UH) Seidman Cancer Center and Case Western Reserve University (CWRU). He obtained his medical degree from Vanderbilt Medical School and completed his radiation oncology residency at Memorial Sloan Kettering Cancer Center.

More for you

Share

Biomarkers

A measurable indicator of the severity or presence of some disease state. More generally a biomarker is anything that can be used as an indicator of a particular disease state or some other physiological state of an organism.

Prostate-Specific Antigen (PSA)

Prostate-specific Antigen (PSA) is a substance found in the blood that is made by the prostate gland. A PSA test measures the level of PSA and is the leading method of screening for prostate cancer.

Sign Up for Our Newsletter!

Stay connected with ZERO Prostate Cancer through our newsletter below: